Forest is looking forward to a very likely NDA approval for aclidinium bromide, their treatment for COPD (Chronic Obstructive Pulmonary Disease). The FDA's Pulmonary-Allergy Drugs Advisory Committee, in February 2012, voted 12 to 2 in favor of approving the currently submitted NDA which will have a decision on April 30th, 2012. This, in addition to continued speculation over a takeover by a larger pharmaceutical company might be enough to continue to drive shares higher in the near term.. http://seekingalpha.com/article/484621-likely-approval-spurring-rise-of-forest-laboratories-shares?source=yahoo
"The currently submitted NDA will have a decision on April 30th, 2012." SA is well known IRRELIABLE.
..Forest Laboratories and Almirall Announce FDA has Extended the Review Period for Aclidinium Bromide
Press Release: Forest Laboratories, Inc. – Thu, Mar 29, 2012 2:30 AM EDT
NEW YORK & BARCELONA, Spain--(BUSINESS WIRE)--
Forest Laboratories, Inc. and Almirall, S.A. announced today that the U.S. Food and Drug Administration (FDA) will require a three-month extension to complete its review of the data supporting the New Drug Application (NDA) for aclidinium bromide, a new long-acting antimuscarinic for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). No additional data has been requested by the agency to complete the review. FDA action is now expected by July 2012.